Trial Profile
A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Pesampator (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Therapeutic Use
- Acronyms TALLY
- Sponsors Biogen
- 18 Apr 2022 Status changed from active, no longer recruiting to completed.
- 19 Feb 2022 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 20 Jan 2022 Planned End Date changed from 7 Feb 2022 to 11 Apr 2022.